MAPT and chronic kidney disease: P-tau217, Tau212-221, p-tau181, and Tau181-190 were all increased in CKD+ compared with CKD− (fold increase range: 0.29 [95% CI, 0.11-0.48] to 0.73 [95% CI, 0.47-0.99]; P < .002), except in patients with cognitive impairment, there were no significant differences in p-tau217 in the models not including Aβ and tau pathologies as covariates (Figure 1 and Figure 2).